Adrenocortical carcinoma: Current therapeutic state-of-the-art

Journal of Oncology

Volumn , Issue , 2012, Pages

  Lebastchi, Amir H ^a   Kunstman, John W ^a   Carling, Tobias ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; BETA CATENIN; CISPLATIN; CIXUTUMUMAB; CYTOTOXIC AGENT; DOVITINIB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; ETOPOSIDE; FIGITUMUMAB; GEFITINIB; LINSITINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOTANE; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN B; SOMATOMEDIN C; SORAFENIB; STEROIDOGENIC FACTOR 1; STREPTOZOCIN; SUNITINIB; TARIQUIDAR; TEMSIROLIMUS; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR MARKER; UNINDEXED DRUG; VASCULOTROPIN; WNT PROTEIN;

ADRENAL CORTEX CARCINOMA; ADRENALECTOMY; ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CARCINOGENESIS; DRUG CHOICE; DRUG DESIGN; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION PROFILING; HUMAN; LAPAROSCOPIC SURGERY; MICROARRAY ANALYSIS; NAUSEA; NEUROTOXICITY; NONHUMAN; OVERALL SURVIVAL; PATIENT SELECTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; REVIEW; TREATMENT RESPONSE; VOMITING;

EID: 84869025734     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2012/234726     Document Type: Review

References (109)

1. Wajchenberg B. L., Albergaria Pereira M. A., Medonca B. B., Adrenocortical carcinoma: clinical and laboratory observations. Cancer 2000 88 4 711 736 (Pubitemid 30091090)
2. Fassnacht M., Wittekind C., Allolio B., Current TNM classification systems for adrenocortical carcinoma. Pathologe 2010 31 5 374 378 2-s2.0-77957583312 10.1007/s00292-010-1306-1
3. Soon P. S. H., McDonald K. L., Robinson B. G., Sidhu S. B., Molecular markers and the pathogenesis of adrenocortical cancer. Oncologist 2008 13 5 548 561 2-s2.0-45749105609 10.1634/theoncologist.2007-0243 (Pubitemid 351872872)
4. Fassnacht M., Allolio B., Clinical management of adrenocortical carcinoma. Best Practice and Research 2009 23 2 273 289 2-s2.0-66149163113 10.1016/j.beem.2008.10.008
5. Zini L., Porpiglia F., Fassnacht M., Contemporary management of adrenocortical carcinoma. European Urology 2011 60 5 1055 1065 2-s2.0-79961112038 10.1016/j.eururo.2011.07.062
6. Weiss L. M., Medeiros L. J., Vickery A. L., Pathologic features of prognostic significance in adrenocortical carcinoma. American Journal of Surgical Pathology 1989 13 3 202 206 2-s2.0-0024513504 (Pubitemid 19081702)
7. Boland G. W. L., Blake M. A., Hahn P. F., Mayo-Smith W. W., Incidental adrenal lesions: principles, techniques, and algorithms for imaging characterization. Radiology 2008 249 3 756 775 2-s2.0-58149200067 10.1148/radiol.2493070976
8. Young W. F. Jr., Conventional imaging in adrenocortical carcinoma: update and perspectives. Hormones and Cancer 2011 2 6 341 347
9. Hamrahian A. H., Ioachimescu A. G., Remer E. M., Motta-Ramirez G., Bogabathina H., Levin H. S., Reddy S., Gill I. S., Siperstein A., Bravo E. L., Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: cleveland clinic experience. Journal of Clinical Endocrinology and Metabolism 2005 90 2 871 877 2-s2.0-20044384532 10.1210/jc.2004-1627 (Pubitemid 40279211)
10. Arlt W., Biehl M., Taylor A. E., Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. The Journal of Clinical Endocrinology and Metabolism 2011 96 12 3775 3784
11. Phan A. T., Adrenal cortical carcinoma-review of current knowledge and treatment practices. Hematology/Oncology Clinics of North America 2007 21 3 489 507 2-s2.0-34249811195 10.1016/j.hoc.2007.04.007 (Pubitemid 46844860)
12. Lughezzani G., Sun M., Perrotte P., Jeldres C., Alasker A., Isbarn H., Budäus L., Shariat S. F., Guazzoni G., Montorsi F., Karakiewicz P. I., The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. European Journal of Cancer 2010 46 4 713 719 2-s2.0-76049095621 10.1016/j.ejca.2009.12.007
13. Allolio B., Fassnacht M., Clinical review: adrenocortical carcinoma: clinical update. Journal of Clinical Endocrinology and Metabolism 2006 91 6 2027 2037 2-s2.0-33744952176 10.1210/jc.2005-2639 (Pubitemid 43854976)
14. Fassnacht M., Johanssen S., Quinkler M., Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 2009 115 2 243 250 2-s2.0-73149088410
15. Kebebew E., Reiff E., Duh Q. Y., Clark O. H., McMillan A., Extent of disease at presentation and outcome for adrenocortical carcinoma: Have we made progress? World Journal of Surgery 2006 30 5 872 878 2-s2.0-33646593777 10.1007/s00268-005-0329-x (Pubitemid 43724119)
16. Sullivan M., Boileau M., Hodges C. V., Adrenal cortical carcinoma. Journal of Urology 1978 120 6 660 665 2-s2.0-0018249921 (Pubitemid 9091388)
17. Icard P., Goudet P., Charpenay C., Andreassian B., Carnaille B., Chapuis Y., Cougard P., Henry J. F., Proye C., Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group. World Journal of Surgery 2001 25 7 891 897 2-s2.0-0034917097 10.1007/s00268-001-0047-y (Pubitemid 32666390)
18. DeLellis R. A., Pathology and Genetics of Tumours of Endocrine Organs. World Health Organization Classification of Tumours 2004 Lyon, France IARC Press
19. Gonzalez R. J., Shapiro S., Sarlis N., Vassilopoulou-Sellin R., Perrier N. D., Evans D. B., Lee J. E., Inabnet W. B., Libutti S. K., Chen H., Duh Q. Y., Wilhelm S., Laparoscopic resection of adrenal cortical carcinoma: a cautionary note. Surgery 2005 138 6 1078 1085 2-s2.0-29144439154 10.1016/j.surg.2005.09.012 (Pubitemid 41797348)
20. Crucitti F., Bellantone R., Ferrante A., Boscherini M., Crucitti P., Carbone G., Casaccia M., Campisi C., Cavallaro A., Sapienza P., Del Gaudio A., Solidoro G., Dettori G., Marogna P., Di Giovanni V., Colli R., Doglietto G., Gozzetti G., Maldarizzi F., The italian registry for adrenal cortical carcinoma: analysis of a multiinstitutional series of 129 patients. Surgery 1996 119 2 161 170 2-s2.0-0029670955 10.1016/S0039-6060(96)80164-4 (Pubitemid 26052933)
21. Terzolo M., Pia A., Berruti A., Osella G., Alì A., Carbone V., Testa E., Dogliotti L., Angeli A., Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. Journal of Clinical Endocrinology and Metabolism 2000 85 6 2234 2238 2-s2.0-0034457107 10.1210/jc.85.6.2234 (Pubitemid 32269248)
22. Terzolo M., Angeli A., Fassnacht M., Adjuvant mitotane treatment for adrenocortical carcinoma. The New England Journal of Medicine 2007 356 23 2372 2380 (Pubitemid 46883771)
23. Kendrick M. L., Lloyd R., Erickson L., Farley D. R., Grant C. S., Thompson G. B., Rowland C., Young W. F., Van Heerden J. A., Adrenocortical carcinoma: surgical progress or status quo? Archives of Surgery 2001 136 5 543 549 2-s2.0-0035022726 (Pubitemid 32417544)
24. Henry J. F., Sebag F., Iacobone M., Mirallie E., Results of laparoscopic adrenalectomy for large and potentially malignant tumors. World Journal of Surgery 2002 26 8 1043 1047 2-s2.0-0036688544 10.1007/s00268-002-6666-0 (Pubitemid 36920306)
25. Porpiglia F., Fiori C., Tarabuzzi R., Giraudo G., Garrone C., Morino M., Fontana D., Scarpa R. M., Is laparoscopic adrenalectomy feasible for adrenocortical carcinoma or metastasis? BJU International 2004 94 7 1026 1029 2-s2.0-9644291501 10.1111/j.1464-410X.2004.05098.x (Pubitemid 39577088)
26. Corcione F., Miranda L., Marzano E., Capasso P., Cuccurullo D., Settembre A., Pirozzi F., Laparoscopic adrenalectomy for malignant neoplasm: our experience in 15 cases. Surgical Endoscopy and Other Interventional Techniques 2005 19 6 841 844 2-s2.0-24044491605 10.1007/s00464-004-9161-x (Pubitemid 41215990)
27. Palazzo F. F., Sebag F., Sierra M., Ippolito G., Souteyrand P., Henry J. F., Long-term outcome following laparoscopic adrenalectomy for large solid adrenal cortex tumors. World Journal of Surgery 2006 30 5 893 898 2-s2.0-33646544679 10.1007/s00268-005-0288-2 (Pubitemid 43724123)
28. Lombardi C. P., Raffaelli M., De Crea C., Bellantone R., Role of laparoscopy in the management of adrenal malignancies. Journal of Surgical Oncology 2006 94 2 128 131 2-s2.0-33747120678 10.1002/jso.20599 (Pubitemid 44267193)
29. Liao C. H., Chueh S. C., Lai M. K., Hsiao P. J., Chen J., Laparoscopic adrenalectomy for potentially malignant adrenal tumors greater than 5 centimeters. Journal of Clinical Endocrinology and Metabolism 2006 91 8 3080 3083 2-s2.0-33747727521 10.1210/jc.2005-2420 (Pubitemid 44271759)
30. Nocca D., Aggarwal R., Mathieu A., Blanc P. M., Denève E., Salsano V., Figueira G., Sanders G., Domergue J., Millat B., Fabre P. R., Laparoscopic surgery and corticoadrenalomas. Surgical Endoscopy and Other Interventional Techniques 2007 21 8 1373 1376 2-s2.0-34547184964 10.1007/s00464-007-9218-8 (Pubitemid 47125060)
31. Ramacciato G., Mercantini P., Torre M. L., Benedetto F. D., Ercolani G., Ravaioli M., Piccoli M., Melotti G., Is laparoscopic adrenalectomy safe and effective for adrenal masses larger than 7 cm? Surgical Endoscopy and Other Interventional Techniques 2008 22 2 516 521 2-s2.0-39049129246 10.1007/s00464-007-9508-1 (Pubitemid 351238246)
32. Brix D., Allolio B., Fenske W., Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. European Urology 2010 58 6 e53 2-s2.0-78049474509 10.1016/j.eururo.2010.09.001
33. Miller B. S., Ammori J. B., Gauger P. G., Broome J. T., Hammer G. D., Doherty G. M., Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma. World Journal of Surgery 2010 34 6 1380 1385 2-s2.0-77955552177 10.1007/s00268-010-0532-2
34. Lee J. E., Berger D. H., El-Naggar A. K., Hickey R. C., Vassilopoulou-Sellin R., Gagel R. F., Burgess M. A., Evans D. B., Moley J., Pasieka J., Capuzzi D., Prinz R., Surgical management, DNA content, and patient survival in adrenal cortical carcinoma. Surgery 1995 118 6 1090 1098 2-s2.0-0028828149 10.1016/S0039-6060(05)80119-9
35. Schulick R. D., Brennan M. F., Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Annals of Surgical Oncology 1999 6 8 719 726 2-s2.0-0033396346 (Pubitemid 30013647)
36. Schteingart D. E., Doherty G. M., Gauger P. G., Giordano T. J., Hammer G. D., Korobkin M., Worden F. P., Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocrine-Related Cancer 2005 12 3 667 680 2-s2.0-17644399691 10.1677/erc.1.01029 (Pubitemid 41483000)
37. Chiche L., Dousset B., Kieffer E., Chapuis Y., Adrenocortical carcinoma extending into the inferior vena cava: presentation of a 15-patient series and review of the literature. Surgery 2006 139 1 15 27 2-s2.0-29144452028 10.1016/j.surg.2005.05.014 (Pubitemid 41814428)
38. Reibetanz J., Jurowich C., Erdogan I., Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Annals of Surgery 2012 255 2 363 369
39. Bellantone R., Ferrante A., Boscherini M., Lombardi C. P., Crucitti P., Crucitti F., Favia G., Borrelli D., Boffi L., Capussotti L., Carbone G., Casaccia M., Cavallaro A., Del Gaudio A., Dettori G., Di Giovanni V., Mazziotti A., Marrano D., Masenti E., Miccoli P., Mosca F., Mussa A., Petronio R., Piat G., Ruberti U., Serio G., Marzano L., Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery 1997 122 6 1212 1218 2-s2.0-13144260715 10.1016/S0039-6060(97)90229-4 (Pubitemid 28016693)
40. Icard P., Chapuis Y., Andreassian B., Bernard A., Proye C., Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery 1992 112 6 972 980 2-s2.0-0027087416 (Pubitemid 23008221)
41. Smith C. D., Weber C. J., Amerson J. R., Laparoscopic adrenalectomy: new gold standard. World Journal of Surgery 1999 23 4 389 396 2-s2.0-0032975465 (Pubitemid 29136130)
42. Gill I. S., The case for laparoscopic adrenalectomy. Journal of Urology 2001 166 2 429 436 2-s2.0-0034947335 (Pubitemid 32652217)
43. Porpiglia F., Fiori C., Daffara F., Zaggia B., Bollito E., Volante M., Berruti A., Terzolo M., Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. European Urology 2010 57 5 873 878 2-s2.0-77949486954 10.1016/j.eururo.2010.01.036
44. Lombardi C. P., Raffaelli M., Boniardi M., Adrenocortical carcinoma: effect of hospital volume on patient outcome. Langenbeck's Archives of Surgery 2012 397 2 201 207
45. Park H. S., Roman S. A., Sosa J. A., Outcomes from 3144 adrenalectomies in the United States: which matters more, surgeon volume or specialty? Archives of Surgery 2009 144 11 1060 1067 2-s2.0-72749114280 10.1001/archsurg.2009.191
46. Schulick R. D., Brennan M. F., Adrenocortical carcinoma. World Journal of Urology 1999 17 1 26 34 2-s2.0-0033069954
47. Luton J. P., Cerdas S., Billaud L., Thomas G., Guilhaume B., Bertagna X., Laudat M. H., Louvel A., Chapuis Y., Blondeau P., Bonnin A., Bricaire H., Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. The New England Journal of Medicine 1990 322 17 1195 1201 2-s2.0-0025248241 (Pubitemid 20137851)
48. Hutter A. M. Jr., Kayhoe D. E., Adrenal cortical carcinoma. Clinical features of 138 patients. The American Journal of Medicine 1966 41 4 572 580 2-s2.0-0013961931
49. Lipsett M. B., Hertz R., Ross G. T., Clinical and pathophysiologic aspects of adrenocortical carcinoma. The American Journal of Medicine 1963 35 3 374 383 2-s2.0-0001531986
50. Cohn K., Gottesman L., Brennan M., Adrenocortical carcinoma. Surgery 1986 100 6 1170 1177 2-s2.0-0022878520 (Pubitemid 17223238)
51. Percarpio B., Knowlton A. H., Radiation therapy of adrenal corticol carcinoma. Acta Radiologica 1976 15 4 288 292 2-s2.0-0017108917
52. Rodgers S. E., Adrenocortical carcinoma. Surgical Oncology Clinics of North America 2006 15 3 535 553 (Pubitemid 44119210)
53. Polat B., Fassnacht M., Pfreundner L., Guckenberger M., Bratengeier K., Johanssen S., Kenn W., Hahner S., Allolio B., Flentje M., Radiotherapy in adrenocortical carcinoma. Cancer 2009 115 13 2816 2823 2-s2.0-67649622025 10.1002/cncr.24331
54. Hermsen I. G. C., Groenen Y. E., Dercksen M. W., Theuws J., Haak H. R., Response to radiation therapy in adrenocortical carcinoma. Journal of Endocrinological Investigation 2010 33 10 712 714 2-s2.0-79951667879 10.3275/6904
55. Milgrom S. A., Goodman K. A., The role of radiation therapy in the management of adrenal carcinoma and adrenal metastases. Journal of Surgical Oncology 2012 106 5 647 650
56. Sabolch A., Feng M., Griffith K., Hammer G., Doherty G., Ben-Josef E., Adjuvant and definitive radiotherapy for adrenocortical carcinoma. International Journal of Radiation Oncology Biology Physics 2011 80 5 1477 1484 2-s2.0-79960104319 10.1016/j.ijrobp.2010.04.030
57. Fassnacht M., Hahner S., Polat B., Koschker A. C., Kenn W., Flentje M., Allolio B., Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 2006 91 11 4501 4504 2-s2.0-33751529232 10.1210/jc.2006-1007 (Pubitemid 44833430)
58. Schteingart D. E., Adjuvant mitotane therapy of adrenal canceruse and controversy. The New England Journal of Medicine 2007 356 23 2415 2418 2-s2.0-34249996792 10.1056/NEJMe078087 (Pubitemid 46883778)
59. Lafemina J., Brennan M. F., Adrenocortical carcinoma: past, present, and future. Journal of Surgical Oncology 2012 106 5 586 594
60. Haak H. R., Hermans J., Van de Velde C. J. H., Lentjes E. G. W. M., Goslings B. M., Fleuren G. J., Krans H. M. J., Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. British Journal of Cancer 1994 69 5 947 951 2-s2.0-0028208020 (Pubitemid 24140681)
61. van Slooten H., Moolenaar A. J., Van Seters A. P., Smeenk D., The treatment of adenocortical carcinoma with o,p′-DDD: prognostic simplications of serum level monitoring. European Journal of Cancer and Clinical Oncology 1984 20 1 47 53 2-s2.0-0021289017 (Pubitemid 14224356)
62. Baudin E., Pellegriti G., Bonnay M., Impact of monitoring plasma 1, 1-dichlorodiphenildichloroethane (o, p′DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 2001 92 6 1385 1392 (Pubitemid 32947821)
63. Faggiano A., Leboulleux S., Young J., Schlumberger M., Baudin E., Rapidly progressing high o,p'DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results. Clinical Endocrinology 2006 64 1 110 113 2-s2.0-33644934697 10.1111/j.1365-2265. 2005.02403.x
64. Daffara F., de Francia S., Reimondo G., Zaggia B., Aroasio E., Porpiglia F., Volante M., Termine A., di Carlo F., Dogliotti L., Angeli A., Berruti A., Terzolo M., Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocrine-Related Cancer 2008 15 4 1043 1053 2-s2.0-58249103034 10.1677/ERC-08-0103
65. Vassilopoulou-Sellin R., Guinee V. F., Klein M. J., Taylor S. H., Hess K. R., Schultz P. N., Samaan N. A., Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 1993 71 10 3119 3123 2-s2.0-0027190328 (Pubitemid 23145548)
66. Bodie B., Novick A. C., Pontes J. E., Straffon R. A., Montie J. E., Babiak T., Sheeler L., Schumacher P., The Cleveland Clinic experience with adrenal cortical carcinoma. Journal of Urology 1989 141 2 257 260 2-s2.0-0024582517 (Pubitemid 19061293)
67. Kasperlik-Zaluska A. A., Migdalska B. M., Zgliczyski S., Makowska A. M., Adrenocortical carcinoma. A clinical study and treatment results of 52 patients. Cancer 1995 75 10 2587 2591
68. Berruti A., Fassnacht M., Baudin E., Hammer G., Haak H., Leboulleux S., Skogseid B., Allolio B., Terzolo M., Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. Journal of Clinical Oncology 2010 28 23 e401 e402 2-s2.0-77957262044 10.1200/JCO.2009.27. 5958
69. Hahner S., Fassnacht M., Mitotane for adrenocortical carcinoma treatment. Current Opinion in Investigational Drugs 2005 6 4 386 394 2-s2.0-17644420335 (Pubitemid 40561415)
70. Wängberg B., Khorram-Manesh A., Jansson S., Nilsson B., Nilsson O., Jakobsson C. E., Lindstedt S., Odén A., Ahlman H., The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Endocrine-Related Cancer 2010 17 1 265 272 2-s2.0-77449130262 10.1677/ERC-09-0190
71. Ilias I., Alevizaki M., Philippou G., Anastasiou E., Souvatzoglou A., Sustained remission of metastatic adrenal carcinoma during long-term administration of low-dose mitotane. Journal of Endocrinological Investigation 2001 24 7 532 535 2-s2.0-0034927782 (Pubitemid 32691168)
72. Gonzalez R. J., Tamm E. P., Ng C., Phan A. T., Vassilopoulou-Sellin R., Perrier N. D., Evans D. B., Lee J. E., Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma. Surgery 2007 142 6 867 875 2-s2.0-36649005347 10.1016/j.surg.2007.09.006 (Pubitemid 350193248)
73. Khan T. S., Imam H., Juhlin C., Skogseid B., Gröndal S., Tibblin S., Wilander E., Öberg K., Eriksson B., Streptozocin and o,p′DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Annals of Oncology 2000 11 10 1281 1287 2-s2.0-0033767891 10.1023/A:1008377915129
74. Berruti A., Terzolo M., Sperone P., Pia A., Della Casa S., Gross D. J., Carnaghi C., Casali P., Porpiglia F., Mantero F., Reimondo G., Angeli A., Dogliotti L., Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocrine-Related Cancer 2005 12 3 657 666 2-s2.0-26944468635 10.1677/erc.1.01025 (Pubitemid 41482999)
75. Fassnacht M., Terzolo M., Allolio B., Combination chemotherapy in advanced adrenocortical carcinoma. The New England Journal of Medicine 2012 366 23 2189 2197
76. Giordano T. J., Thomas D. G., Kuick R., Lizyness M., Misek D. E., Smith A. L., Sanders D., Aljundi R. T., Gauger P. G., Thompson N. W., Taylor J. M. G., Hanash S. M., Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. American Journal of Pathology 2003 162 2 521 531 2-s2.0-0037331277 (Pubitemid 36267859)
77. de Fraipont F., El Atifi M., Cherradi N., Moigne G. L., Defaye G., Houlgatte R., Bertherat J., Bertagna X., Plouin P. F., Baudin E., Berger F., Gicquel C., Chabre O., Feige J. J., Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. Journal of Clinical Endocrinology and Metabolism 2005 90 3 1819 1829 2-s2.0-20144386848 10.1210/jc.2004-1075 (Pubitemid 40464057)
78. Soon P. S. H., Gill A. J., Benn D. E., Clarkson A., Robinson B. G., McDonald K. L., Sidhu S. B., Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. Endocrine-Related Cancer 2009 16 2 573 583 2-s2.0-67650480396 10.1677/ERC-08-0237
79. Velázquez-Fernández D., Laurell C., Geli J., Höög A., Odeberg J., Kjellman M., Lundeberg J., Hamberger B., Nilsson P., Bäckdahl M., Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. Surgery 2005 138 6 1087 1094 2-s2.0-29144437760 10.1016/j.surg.2005.09.031 (Pubitemid 41797349)
80. Slater E. P., Diehl S. M., Langer P., Samans B., Ramaswamy A., Zielke A., Bartsch D. K., Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. European Journal of Endocrinology 2006 154 4 587 598 2-s2.0-33646043449 10.1530/eje.1.02116
81. Szabó P. M., Tamási V., Molnár V., Andrásfalvy M., Tömböl Z., Farkas R., Kövesdi K., Patócs A., Tóth M., Szalai C., Falus A., Rácz K., Igaz P., Meta-analysis of adrenocortical tumour genomics data: novel pathogenic pathways revealed. Oncogene 2010 29 21 3163 3172 2-s2.0-77952953203 10.1038/onc.2010.80
82. Gicquel C., Bertagna X., Gaston V., Coste J., Louvel A., Baudin E., Bertherat J., Chapuis Y., Duclos J. M., Schlumberger M., Plouin P. F., Luton J. P., Le Bouc Y., Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Research 2001 61 18 6762 6767 2-s2.0-0035884186 (Pubitemid 32896498)
83. Gicquel C., Raffin-Sanson M. L., Gaston V., Bertagna X., Plouin P. F., Schlumberger M., Louvel A., Luton J. P., Le Bouc Y., Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. Journal of Clinical Endocrinology and Metabolism 1997 82 8 2559 2565 2-s2.0-0030840738 10.1210/jc.82.8.2559 (Pubitemid 27337873)
84. Arora A., Scholar E. M., Role of tyrosine kinase inhibitors in cancer therapy. Journal of Pharmacology and Experimental Therapeutics 2005 315 3 971 979 2-s2.0-27544479318 10.1124/jpet.105.084145 (Pubitemid 41635382)
85. Quinkler M., Hahner S., Wortmann S., Johanssen S., Adam P., Ritte C., Strasburger C., Allolio B., Fassnacht M., Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. Journal of Clinical Endocrinology and Metabolism 2008 93 6 2057 2062 2-s2.0-45149110737 10.1210/jc.2007-2564 (Pubitemid 351831515)
86. Wortmann S., Quinkler M., Ritter C., Kroiss M., Johanssen S., Hahner S., Allolio B., Fassnacht M., Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. European Journal of Endocrinology 2010 162 2 349 356 2-s2.0-75149143015 10.1530/EJE-09-0804
87. Fassnacht M., Kreissl M. C., Weismann D., Allolio B., New targets and therapeutic approaches for endocrine malignancies. Pharmacology and Therapeutics 2009 123 1 117 141 2-s2.0-65749120532 10.1016/j.pharmthera.2009.03.013
88. Berruti A., Ferrero A., Sperone P., Daffara F., Reimondo G., Papotti M., Dogliotti L., Angeli A., Terzolo M., Emerging drugs for adrenocortical carcinoma. Expert Opinion on Emerging Drugs 2008 13 3 497 509 2-s2.0-53549126060 10.1517/14728214.13.3.497
89. Laurell C., Velázquez-Fernández D., Lindsten K., Transcriptional profiling enables molecular classification of adrenocortical tumours. European Journal of Endocrinology 2009 161 1 141 152
90. Fernandez-Ranvier G. G., Weng J., Yeh R. F., Khanafshar E., Suh I., Barker C., Duh Q. Y., Clark O. H., Kebebew E., Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling. Archives of Surgery 2008 143 9 841 846 2-s2.0-52249109610 10.1001/archsurg.143.9.841
91. Haluska P., Worden F., Olmos D., Yin D., Schteingart D., Batzel G. N., Paccagnella M. L., De Bono J. S., Gualberto A., Hammer G. D., Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemotherapy and Pharmacology 2010 65 4 765 773 2-s2.0-75749102231 10.1007/s00280-009-1083-9
92. Mulvihill M. J., Cooke A., Rosenfeld-Franklin M., Buck E., Foreman K., Landfair D., Oconnor M., Pirritt C., Sun Y., Yao Y., Arnold L. D., Gibson N. W., Ji Q. S., Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Medicinal Chemistry 2009 1 6 1153 1171 2-s2.0-77952060250 10.4155/fmc.09.89
93. Faivre S., Kroemer G., Raymond E., Current development of mTOR inhibitors as anticancer agents. Nature Reviews Drug Discovery 2006 5 8 671 688 2-s2.0-33746637660 10.1038/nrd2062 (Pubitemid 44151605)
94. Doghman M., El Wakil A., Cardinaud B., Thomas E., Wang J., Zhao W., Peralta-Del Valle M. H. C., Figueiredo B. C., Zambetti G. P., Lalli E., Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by MicroRNA in childhood adrenocortical tumors. Cancer Research 2010 70 11 4666 4675 2-s2.0-77953168294 10.1158/0008-5472.CAN-09-3970
95. Naing A., Kurzrock R., Burger A., Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clinical Cancer Research 2011 17 18 6052 6060
96. MacDonald B. T., Tamai K., He X., Wnt/ β -catenin signaling: components, mechanisms, and diseases. Developmental Cell 2009 17 1 9 26 2-s2.0-67650230896 10.1016/j.devcel.2009.06.016
97. Assie G., Giordano T. J., Bertherat J., Gene expression profiling in adrenocortical neoplasia. Molecular and Cellular Endocrinology 2012 351 1 111 117
98. Ragazzon B., Assié G., Bertherat J., Transcriptome analysis of adrenocortical cancers: from molecular classification to the identification of new treatments. Endocrine-Related Cancer 2011 18 2 R15 R27 2-s2.0-79953165342 10.1530/ERC-10-0220
99. Tissier F., Cavard C., Groussin L., Perlemoine K., Fumey G., Hagneré A. M., René-Corail F., Jullian E., Gicquel C., Bertagna X., Vacher-Lavenu M. C., Perret C., Bertherat J., Mutations of β -catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Research 2005 65 17 7622 7627 2-s2.0-24744454197 10.1158/0008-5472.CAN-05-0593 (Pubitemid 41297234)
100. Berthon A., Sahut-Barnola I., Lambert-Langlais S., de Joussineau C., Damon-Soubeyrand C., Louiset E., Taketo M. M., Tissier F., Bertherat J., Lefranois-Martinez A. M., Martinez A., Val P., Constitutive β -catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Human Molecular Genetics 2010 19 8 1561 1576 2-s2.0-77952300541 10.1093/hmg/ddq029
101. Schimmer B. P., White P. C., Minireview: steroidogenic factor 1: its roles in differentiation, development, and disease. Molecular Endocrinology 2010 24 7 1322 1337 2-s2.0-77954832944 10.1210/me.2009-0519
102. Figueiredo B. C., Cavalli L. R., Pianovski M. A., Amplification of the steroidogenic factor 1 gene in childhood adrenocortical tumors. The Journal of Clinical Endocrinology & Metabolism 2005 90 2 615 619 (Pubitemid 40279170)
103. Pianovski M. A. D., Cavalli L. R., Figueiredo B. C., Santos S. C. L., Doghman M., Ribeiro R. C., Oliveira A. G., Michalkiewicz E., Rodrigues G. A., Zambetti G., Haddad B. R., Lalli E., SF-1 overexpression in childhood adrenocortical tumours. European Journal of Cancer 2006 42 8 1040 1043 2-s2.0-33646521924 10.1016/j.ejca.2006.01.022
104. Doghman M., Karpova T., Rodrigues G. A., Arhatte M., De Moura J., Cavalli L. R., Virolle V., Barbry P., Zambetti G. P., Figueiredo B. C., Heckert L. L., Lalli E., Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer. Molecular Endocrinology 2007 21 12 2968 2987 2-s2.0-36849073202 10.1210/me.2007-0120 (Pubitemid 350223508)
105. Doghman M., Cazareth J., Douguet D., Madoux F., Hodder P., Lalli E., Inhibition of adrenocortical carcinoma cell proliferation by steroidogenic factor-1 inverse agonists. Journal of Clinical Endocrinology and Metabolism 2009 94 6 2178 2183 2-s2.0-66749179396 10.1210/jc.2008-2163
106. Demeure M. J., Bussey K. J., Kirschner L. S., Targeted therapies for adrenocortical carcinoma: IGF and beyond. Horm Cancer 2011 2 6 385 392
107. Ronchi C. L., Sbiera S., Kraus L., Wortmann S., Johanssen S., Adam P., Willenberg H. S., Hahner S., Allolio B., Fassnacht M., Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. Endocrine-Related Cancer 2009 16 3 907 918 2-s2.0-72749100910 10.1677/ERC-08-0224
108. Mistry P., Stewart A. J., Dangerfield W., Okiji S., Liddle C., Bootle D., Plumb J. A., Templeton D., Charlton P., In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Research 2001 61 2 749 758 2-s2.0-0035863315 (Pubitemid 32128642)
109. Walker J., Martin C., Callaghan R., Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. European Journal of Cancer 2004 40 4 594 605 2-s2.0-1242338943 10.1016/j.ejca.2003.09.036 (Pubitemid 38220779)